Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Cabozantinib + Nivolumab & Renal cell carcinoma (RCC), cabozantinib + nivolumab is approved as first‑line treatment for adults with advanced Renal cell carcinoma (RCC), based on the phase III CheckMate 9ER trial, where the combination improved progression‑free survival, overall survival, and objective response versus sunitinib, leading to its authorization as an ICI/TKI doublet in this setting (1).
The same nivolumab + cabozantinib regimen is authorized in the EU for first‑line treatment of advanced Renal cell carcinoma (RCC), with the label reflecting the CheckMate 9ER data and positioning it as an approved frontline option alongside …